Company Filing History:
Years Active: 2022-2023
Title: Innovations of Jae-Sung Yang in Metabolic Disease Treatment
Introduction
Jae-Sung Yang is a prominent inventor based in Seoul, South Korea. He has made significant contributions to the field of metabolic disease treatment through his innovative research and development of peptide analogs. With a total of two patents to his name, Yang is recognized for his work in addressing obesity and diabetes.
Latest Patents
Yang's latest patents focus on the development of acylated oxyntomodulin peptide analogs. These novel peptide analogs are designed to prevent and treat obesity or overweightness, as well as diabetes associated with these conditions. The pharmaceutical compositions containing these peptide analogs demonstrate superior efficacy compared to wild-type oxyntomodulin, particularly in dual agonism on GLP-1 and glucagon receptors. Additionally, these analogs exhibit a longer in vivo half-life, making them a promising option for the treatment of metabolic diseases.
Career Highlights
Jae-Sung Yang is currently associated with Dong-a St Co., Ltd., where he continues to advance his research in metabolic health. His work has garnered attention for its potential to improve treatment outcomes for individuals suffering from obesity and diabetes. Yang's innovative approach to peptide analog development showcases his commitment to addressing critical health challenges.
Collaborations
Yang collaborates with notable colleagues, including Kyung-Seok Lee and Yu-Na Chae. Their combined expertise contributes to the advancement of research in the field of metabolic diseases.
Conclusion
Jae-Sung Yang's contributions to the development of acylated oxyntomodulin peptide analogs represent a significant advancement in the treatment of obesity and diabetes. His innovative work continues to pave the way for new therapeutic options in metabolic health.